RT Journal Article
SR Electronic
T1 Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187112
DO 10.1101/2020.09.03.20187112
A1 Cruz, Leticia R.
A1 Baladrón, Idania
A1 Rittoles, Aliusha
A1 Díaz, Pablo A.
A1 Valenzuela, Carmen
A1 Santana, Raúl
A1 Vázquez, Maria M.
A1 García, Ariadna
A1 Chacón, Deyli
A1 Thompson, Delvin
A1 Perera, Gustavo
A1 González, Ariel
A1 Reyes, Rafael
A1 Torres, Loida
A1 Pérez, Jesus
A1 Vázquez, Dania M.
A1 Lemus, Gilda
A1 Rosales, Mauro
A1 Ramón, Ailyn C.
A1 Perez, George V.
A1 Guillén, Gerardo
A1 Muzio, Verena
A1 Perera, Yasser
A1 Perea, Silvio E.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/09/15/2020.09.03.20187112.abstract
AB Background The recently discovered instrumental role of CK2 in the SARS-Cov2 infection has pointed out this protein kinase as a promising therapeutic target in Covid-19 disease. Accordingly, anti-SARS-Cov2 activity has been reported by CK2 inhibitors in vitro, however any anti-CK2 clinical approach has been assessed in Covid-19 patients so far. Here, we investigated the putative clinical benefit of CIGB-325, an anti-CK2 peptide previously used in cancer patients, which was added to the standard-of-care to treat Covid-19.Methods A monocentric, randomized standard-of-care controlled trial of intravenous CIGB-325 in adults hospitalized with Covid-19. Twenty patients were randomly assigned to receive CIGB-300 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care (10 patients). Primary outcomes were time to viral clearance defined as the time (in days) to have nasopharyngeal SARS-Cov2 negative PCR and clinical response. This trial is registered with https://rpcec.sld.cu/trials/RPCEC00000317-En (Code: IG/CIGB300I/CV/2001).Results Most of the patients had initial positive by chest-computed tomography (CT). CIGB-325 treatment reduced both number of pulmonary lesions and lesion’s extent compared to control group in seven days. Taking into account the Covid-19 chest-CT abnormalities, CIGB-325 was also superior to control as well as in terms of proportion of patients with such clinical benefit. Improvement of clinical status was experienced in 50% of patients in the CIGB-325 group and 25% in control. Accordingly, systemic levels of CPK, LDH and CRP were lowered at day 7 by treating with this anti-CK2 peptide. Both therapeutic regimens were similar respect to SARS-Cov2 clearance in nasopharynx swabs over the time.Conclusion Our study revealed that consecutive-5 day regimen of intravenous CIGB-325 at 2.5 mg/kg quickly improved the chest-CT outcomes over standard-of-care. This is the first report describing signs of clinical benefit of an anti-CK2 approach in Covid-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIG/CIGB300I/CV/2001Funding StatementThis work did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee for Clinical Research in the Luis Diaz Soto Hospital and Cuban Regulatory Agency (CECMED) approved the trial. The study complied with the Good Clinical Practices and the precepts established in the Declaration of the Helsinki World Medical Association. All patients met the inclusion criteria described in the protocol and signed the informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript is available.